|
1
|
Thorens B: Sensing of glucose in the
brain. Handbook Exp Pharmacol. 209:277–294. 2012. View Article : Google Scholar
|
|
2
|
Vogt MC and Brüning JC: CNS insulin
signaling in the control of energy homeostasis and glucose
metabolism - from embryo to old age. Trends Endocrinol Metab.
24:76–84. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nammi S, Koka S, Chinnala KM and Boini KM:
Obesity: An overview on its current perspectives and treatment
options. Nutr J. 3:32004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Taylor RW, Keil D, Gold EJ, Williams SM
and Goulding A: Body mass index, waist girth, and waist-to-hip
ratio as indexes of total and regional adiposity in women:
Evaluation using receiver operating characteristic curves. Am J
Clin Nutr. 67:44–49. 1998.PubMed/NCBI
|
|
5
|
Camargo RL, Torrezan R, de Oliveira JC,
Branco RC, Barella LF, Grassiolli S, Gravena C and Mathias PC: An
increase in glucose concentration in the lateral ventricles of the
brain induces changes in autonomic nervous system activity. Neurol
Res. 35:15–21. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zeng HL, Huang SL, Xie FC, Zeng LM, Hu YH
and Leng Y: Yhhu981, a novel compound, stimulates fatty acid
oxidation via the activation of AMPK and ameliorates lipid
metabolism disorder in ob/ob mice. Acta Pharmacol Sin. 36:343–352.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stachowiak EK, Oommen S, Vasu VT,
Srinivasan M, Stachowiak M, Gohil K and Patel MS: Maternal obesity
affects gene expression and cellular development in fetal brains.
Nutr Neurosci. 16:96–103. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gustafson DR: Adiposity and cognitive
decline: Underlying mechanisms. J Alzheimers Dis. 30(Suppl 2):
S97–S112. 2012.PubMed/NCBI
|
|
9
|
Sriram K, Benkovic SA, Miller DB and
O'Callaghan JP: Obesity exacerbates chemically induced
neurodegeneration. Neuroscience. 115:1335–1346. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Salkovic-Petrisic M, Osmanovic J,
Grünblatt E, Riederer P and Hoyer S: Modeling sporadic Alzheimer's
disease: The insulin resistant brain state generates multiple
long-term morphobiological abnormalities inclusive
hyperphosphorylated tau protein and amyloid-beta. J Alzheimers Dis.
18:729–750. 2009.PubMed/NCBI
|
|
11
|
Ariaans G, de Jong S, Gietema JA, Lefrandt
JD, de Vries EG and Jalving M: Cancer-drug induced insulin
resistance: Innocent bystander or unusual suspect. Cancer Treat
Rev. 41:376–384. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Burghardt PR, Love TM, Stohler CS,
Hodgkinson C, Shen PH, Enoch MA, Goldman D and Zubieta JK: Leptin
regulates dopamine responses to sustained stress in humans. J
Neurosci. 32:15369–15376. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Coyle JT and Puttfarcken P: Oxidative
stress, glutamate, and neurodegenerative disorders. Science.
262:689–695. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
De Luca G, Russo MT, Degan P, Tiveron C,
Zijno A, Meccia E, Ventura I, Mattei E, Nakabeppu Y, Crescenzi M,
et al: A role for oxidized DNA precursors in Huntington's
disease-like striatal neurodegeneration. PLoS Genet.
4:e10002662008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Adam-Vizi V: Production of reactive oxygen
species in brain mitochondria: Contribution by electron transport
chain and non-electron transport chain sources. Antioxid Redox
Signal. 7:1140–1149. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Calabrese V, Sultana R, Scapagnini G,
Guagliano E, Sapienza M, Bella R, Kanski J, Pennisi G, Mancuso C,
Stella AMG, et al: Nitrosative stress, cellular stress response,
and thiol homeostasis in patients with Alzheimer's disease.
Antioxid Redox Signal. 8:1975–1986. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Okouchi M, Ekshyyan O, Maracine M and Aw
TY: Neuronal apoptosis in neurodegeneration. Antioxid Redox Signal.
9:1059–1096. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fernandez-Vizarra P, Lopez-Franco O,
Mallavia B, Higuera-Matas A, Lopez-Parra V, Ortiz-Muñoz G, Ambrosio
E, Egido J, Almeida OF and Gomez-Guerrero C: Immunoglobulin G Fc
receptor deficiency prevents Alzheimer-like pathology and cognitive
impairment in mice. Brain. 135:2826–2837. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li J, Tang Y and Cai D: IKKβ/NF-κB
disrupts adult hypothalamic neural stem cells to mediate a
neurodegenerative mechanism of dietary obesity and pre-diabetes.
Nat Cell Biol. 14:999–1012. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Williamson R, McNeilly A and Sutherland C:
Insulin resistance in the brain: An old-age or new-age problem?
Biochem Pharmacol. 84:737–745. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hallschmid M and Schultes B: Central
nervous insulin resistance: A promising target in the treatment of
metabolic and cognitive disorders? Diabetologia. 52:2264–2269.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
de la Monte SM: Insulin resistance and
Alzheimer's disease. BMB Rep. 42:475–481. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Roriz-Filho SJ, Sá-Roriz TM, Rosset I,
Camozzato AL, Santos AC, Chaves ML, Moriguti JC and Roriz-Cruz M:
(Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta.
1792:432–443. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Driscoll I, Beydoun MA, An Y, Davatzikos
C, Ferrucci L, Zonderman AB and Resnick SM: Midlife obesity and
trajectories of brain volume changes in older adults. Hum Brain
Mapp. 33:2204–2210. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kaidanovich-Beilin O, Cha DS and McIntyre
RS: Crosstalk between metabolic and neuropsychiatric disorders.
F1000 Biol Rep. 4:142012. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Morris JK, Zhang H, Gupte AA, Bomhoff GL,
Stanford JA and Geiger PC: Measures of striatal insulin resistance
in a 6-hydroxydopamine model of Parkinson's disease. Brain Res.
1240:185–195. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Koren R, Toledano Y and Hod M: The use of
insulin detemir during pregnancy: A safety evaluation. Expert Opin
Drug Saf. 14:593–599. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fantasia HC: Inhaled insulin - a new
delivery for an old drug. Nurs Womens Health. 19:67–70. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ford RJ, Fullerton MD, Pinkosky SL, Day
EA, Scott JW, Oakhill JS, Bujak AL, Smith BK, Crane JD, Blümer RM,
et al: Metformin and salicylate synergistically activate liver
AMPK, inhibit lipogenesis and improve insulin sensitivity. Biochem
J. 468:125–132. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
White JR Jr: Empagliflozin, an SGLT2
inhibitor for the treatment of type 2 diabetes mellitus: A review
of the evidence. Ann Pharmacother. 49:582–598. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ramadan WH and Kabbara WK:
Sitagliptin/Simvastatin: A first combination tablet to treat type 2
diabetes and hypercholesterolemia - a review of its
characteristics. Vasc Health Risk Manag. 11:125–132. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pacini G, Mari A, Fouqueray P, Bolze S and
Roden M: Imeglimin increases glucose-dependent insulin secretion
and improves β-cell function in patients with type 2 diabetes.
Diabetes Obes Metab. 17:541–545. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Uchida S, Mitani A, Gunji E, Takahashi T
and Yamamoto K: In vitro characterization of luseogliflozin, a
potent and competitive sodium glucose co-transporter 2 inhibitor:
Inhibition kinetics and binding studies. J Pharmacol Sci.
128:54–57. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Powell J, Miller SA and Taylor JR:
Sodium-glucose cotransporter 2 inhibitors: The new option for
diabetes mellitus management. South Med J. 108:82–90. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hedrington MS and Davis SN: Ipragliflozin,
a sodium-glucose cotransporter 2 inhibitor, in the treatment of
type 2 diabetes. Expert Opin Drug Metab Toxicol. 11:613–623. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yanai H, Adachi H, Katsuyama H, Moriyama
S, Hamasaki H and Sako A: Causative anti-diabetic drugs and the
underlying clinical factors for hypoglycemia in patients with
diabetes. World J Diabetes. 6:30–36. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tran L, Zielinski A, Roach AH, Jende JA,
Householder AM, Cole EE, Atway SA, Amornyard M, Accursi ML, Shieh
SW, et al: Pharmacologic treatment of type 2 diabetes: oral
medications. Ann Pharmacother. 49:540–556. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zheng J, Woo SL, Hu X, Botchlett R, Chen
L, Huo Y and Wu C: Metformin and metabolic diseases: A focus on
hepatic aspects. Front Med. 9:173–186. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Agid Y: Parkinson's disease:
Pathophysiology. Lancet. 337:1321–1324. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Špolcová A, Mikulášková B, Holubová M,
Nagelová V, Pirnik Z, Zemenová J, Haluzík M, Železná B, Galas MC
and Maletínská L: Anorexigenic lipopeptides ameliorate central
insulin signaling and attenuate tau phosphorylation in hippocampi
of mice with monosodium glutamate-induced obesity. J Alzheimers
Dis. 45:823–835. 2015.PubMed/NCBI
|
|
41
|
Priyadarshini M, Kamal MA, Greig NH,
Realef M, Abuzenadah AM, Chaudhary AG and Damanhouri GA:
Alzheimer's disease and type 2 diabetes: Exploring the association
to obesity and tyrosine hydroxylase. CNS Neurol Disord Drug
Targets. 11:482–489. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Picone P, Nuzzo D, Caruana L, Messina E,
Barera A, Vasto S and Di Carlo M: Metformin increases APP
expression and processing via oxidative stress, mitochondrial
dysfunction and NF-κB activation: Use of insulin to attenuate
metformin's effect. Biochim Biophys Acta. 1853:1046–1059. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Miller DB and O'Callaghan JP: Do
early-life insults contribute to the late-life development of
Parkinson and Alzheimer diseases? Metabolism. 57(Suppl 2): S44–S49.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Song I, Muller C, Louw J and Bouwens L:
Regulating the beta cell mass as a strategy for type-2 diabetes
treatment. Curr Drug Targets. 16:516–524. 2015. View Article : Google Scholar : PubMed/NCBI
|
